Author

Aly Karsan

BC Cancer Agency - Cited by 20,146

Biography

After receiving his MD from Queen’s University in Kingston, Ontario, and a rotating internship at Lion’s Gate Hospital, North Vancouver, BC, Dr. Karsan practiced medicine in rural BC and the Northwest Territories before working as a volunteer with Médecins Sans Frontières. Currently, Dr. Karsan is Professor of Pathology and Laboratory Medicine at UBC and a Distinguished Scientist at Canada's Michael Smith Genome Sciences Centre at BC Cancer. Dr. Karsan has been supported by several prestigious awards over the years.
Title
Cited by
Year
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia
TR Docking, JDK Parker, M Jädersten, G Duns, L Chang, J Jiang, ...Nature Communications 12 (1), 2474, 2021202
46
2021
Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
JE Chu, B Johnson, L Kugathasan, VK Morris, K Raghav, L Swanson, ...Clinical Cancer Research 26 (17), 4599-4605, 2020202
27
2020
Mechanisms of lenalidomide sensitivity and resistance
S Martinez-Høyer, A KarsanExperimental hematology 91, 22-31, 2020202
27
2020
Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing
ML Thibodeau, K O’Neill, K Dixon, C Reisle, KL Mungall, M Krzywinski, ...Genetics in Medicine 22 (11), 1892-1897, 2020202
25
2020
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
RJ Stubbins, A KarsanBlood cancer journal 11 (12), 193, 2021202
22
2021
Inflammation and myeloid malignancy: quenching the flame
RJ Stubbins, U Platzbecker, A KarsanBlood, The Journal of the American Society of Hematology 140 (10), 1067-1074, 2022202
13
2022
Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository
C Mighton, AC Smith, J Mayers, R Tomaszewski, S Taylor, S Hume, ...Journal of Medical Genetics 59 (6), 571-578, 2022202
13
2022
Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
D Weymann, S Pollard, B Chan, E Titmuss, A Bohm, J Laskin, SJM Jones, ...Cancer Medicine 10 (15), 5131-5140, 2021202
11
2021
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer
CC Cheung, AC Smith, R Albadine, G Bigras, A Bojarski, C Couture, ...Lung Cancer 160, 127-135, 2021202
11
2021
MET exon 14 skipping mutation positive non-small cell lung cancer: response to systemic therapy
SK Wong, D Alex, I Bosdet, C Hughesman, A Karsan, S Yip, C HoLung Cancer 154, 142-145, 2021202
8
2021
TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice
A Gopal, R Ibrahim, M Fuller, P Umlandt, J Parker, J Tran, L Chang, ...Journal of Experimental Medicine 219 (3), e2020031, 2022202
7
2022
Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade
MA Berbís, DS McClintock, A Bychkov, J Van der Laak, L Pantanowitz, ...EBioMedicine 88, 2023202
6
2023
Establishing a framework for the clinical translation of germline findings in precision oncology
K Dixon, S Young, Y Shen, ML Thibodeau, A Fok, E Pleasance, E Zhao, ...JNCI Cancer Spectrum 4 (5), pkaa045, 2020202
6
2020
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
S Shickh, LE Oldfield, M Clausen, C Mighton, A Sebastian, A Calvo, ...The Oncologist 27 (5), e393-e01, 2022202
4
2022
Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
JS Kwon, AV Tinker, J Santos, K Compton, S Sun, KA Schrader, A KarsanJCO Precision Oncology 6, e2200033, 2022202
4
2022
Assessing limit of detection in clinical sequencing
ER Starks, L Swanson, TR Docking, I Bosdet, S Munro, RA Moore, ...The Journal of Molecular Diagnostics 23 (), 55-66, 2021202
4
2021
DNA methylation analysis improves the prognostication of acute myeloid leukemia
H Samimi, I Mehta, TR Docking, A Zainulabadeen, A Karsan, H ZareEJHaem 2 (2), 211-218, 2021202
3
2021
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort
RJ Stubbins, M Stamenkovic, C Roy, J Rodrigo, S Chung, ...European Journal of Haematology 108 (5), 437-445, 0
2
2022
Elucidating the importance and regulation of key enhancers for human MEIS1 expression
P Xiang, X Yang, L Escano, I Dhillon, E Schneider, J Clemans-Gibbon, ...Leukemia 36 (8), 1980-1989, 0
2
2022
Loss of FBXO11 function establishes a stem cell program in acute myeloid leukemia through dysregulation of the mitochondrial protease LONP1
Loss of FBXO function establishes a stem cell program in acute myeloid leukemia through dysregulation of the mitochondrial protease LONPA Mo, H Kincross, X Wang, LYT Chang, G Duns, H Kwan, T Lau, ...Blood 40 (Supplement ), 8688-8689, 2022202
1
2022

Referred From: https://scholar.google.ca/citations?user=lIwkNJ4AAAAJ&hl=en

Cited by
Citations 20146
h-index 66
i10-index 164
Recommended Journals
Open Access Journals